Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.
Identifieur interne : 000125 ( PubMed/Curation ); précédent : 000124; suivant : 000126Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.
Auteurs : Tony Y. Zhang [République populaire de Chine] ; Boyu Zhong [République populaire de Chine]Source :
- Medicine in drug discovery [ 2590-0986 ] ; 2020.
Abstract
This paper provides an overview of the current global market and manufacturing landscape for hydroxychloroquine (HCQ). The capacity and capabilities of global producers to meet the potential demand for treating patients inflicted with COVID-19 by the novel corona virus SARS-CoV-2, should HCQ's efficacy be established by more definitive clinical trials, is also assessed. Given the large existing manufacturing base and abundance of raw materials for HCQ, the supply challenge can be met with considerable efforts and international cooperation. Preemptive and coordinated emergency efforts among global governments, regulatory agencies, chemical and pharmaceutical industries are imperative for meeting the surge in demand.
DOI: 10.1016/j.medidd.2020.100036
PubMed: 32292908
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000125
Links to Exploration step
pubmed:32292908Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.</title><author><name sortKey="Zhang, Tony Y" sort="Zhang, Tony Y" uniqKey="Zhang T" first="Tony Y" last="Zhang">Tony Y. Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Zhong, Boyu" sort="Zhong, Boyu" uniqKey="Zhong B" first="Boyu" last="Zhong">Boyu Zhong</name><affiliation wicri:level="1"><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32292908</idno><idno type="pmid">32292908</idno><idno type="doi">10.1016/j.medidd.2020.100036</idno><idno type="wicri:Area/PubMed/Corpus">000125</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000125</idno><idno type="wicri:Area/PubMed/Curation">000125</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000125</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.</title><author><name sortKey="Zhang, Tony Y" sort="Zhang, Tony Y" uniqKey="Zhang T" first="Tony Y" last="Zhang">Tony Y. Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Zhong, Boyu" sort="Zhong, Boyu" uniqKey="Zhong B" first="Boyu" last="Zhong">Boyu Zhong</name><affiliation wicri:level="1"><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai</wicri:regionArea></affiliation></author></analytic><series><title level="j">Medicine in drug discovery</title><idno type="eISSN">2590-0986</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><i>This paper provides an overview of the current global market and manufacturing landscape for hydroxychloroquine (HCQ). The capacity and capabilities of global producers to meet the potential demand for treating patients inflicted with COVID-19 by the novel corona virus</i> SARS-CoV-2<i>, should HCQ's efficacy be established by more definitive clinical trials, is also assessed. Given the large existing manufacturing base and abundance of raw materials for HCQ, the supply challenge can be met with considerable efforts and international cooperation. Preemptive and coordinated emergency efforts among global governments, regulatory agencies, chemical and pharmaceutical industries are imperative for meeting the surge in demand</i>.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32292908</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2590-0986</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Apr</Month><Day>09</Day></PubDate></JournalIssue><Title>Medicine in drug discovery</Title><ISOAbbreviation>Med Drug Discov</ISOAbbreviation></Journal><ArticleTitle>Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.</ArticleTitle><Pagination><MedlinePgn>100036</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medidd.2020.100036</ELocationID><Abstract><AbstractText><i>This paper provides an overview of the current global market and manufacturing landscape for hydroxychloroquine (HCQ). The capacity and capabilities of global producers to meet the potential demand for treating patients inflicted with COVID-19 by the novel corona virus</i> SARS-CoV-2<i>, should HCQ's efficacy be established by more definitive clinical trials, is also assessed. Given the large existing manufacturing base and abundance of raw materials for HCQ, the supply challenge can be met with considerable efforts and international cooperation. Preemptive and coordinated emergency efforts among global governments, regulatory agencies, chemical and pharmaceutical industries are imperative for meeting the surge in demand</i>.</AbstractText><CopyrightInformation>© 2020 The Author(s). Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tony Y</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Boyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Med Drug Discov</MedlineTA><NlmUniqueID>101765689</NlmUniqueID><ISSNLinking>2590-0986</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32292908</ArticleId><ArticleId IdType="doi">10.1016/j.medidd.2020.100036</ArticleId><ArticleId IdType="pii">S2590-0986(20)30023-3</ArticleId><ArticleId IdType="pii">100036</ArticleId><ArticleId IdType="pmc">PMC7144509</ArticleId></ArticleIdList><pmc-dir>pmcsd</pmc-dir>
</PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000125 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000125 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:32292908
|texte= Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32292908" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |